EP3122322A1 - Auswaschfestes chemisches mousse mit adapalen und benzoylperoxid - Google Patents

Auswaschfestes chemisches mousse mit adapalen und benzoylperoxid

Info

Publication number
EP3122322A1
EP3122322A1 EP15712387.8A EP15712387A EP3122322A1 EP 3122322 A1 EP3122322 A1 EP 3122322A1 EP 15712387 A EP15712387 A EP 15712387A EP 3122322 A1 EP3122322 A1 EP 3122322A1
Authority
EP
European Patent Office
Prior art keywords
composition
agents
composition according
generating agent
gas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15712387.8A
Other languages
English (en)
French (fr)
Other versions
EP3122322B1 (de
Inventor
Jean-Christophe Buge
Karine Nadau-Fourcade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Publication of EP3122322A1 publication Critical patent/EP3122322A1/de
Application granted granted Critical
Publication of EP3122322B1 publication Critical patent/EP3122322B1/de
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/38—Percompounds, e.g. peracids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/22—Gas releasing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/88—Two- or multipart kits
    • A61K2800/882—Mixing prior to application

Definitions

  • the present invention relates to a topical product that is not rinsed in the form of a foam for the cosmetic and / or pharmaceutical treatment of the skin, comprising adapalene and peroxide. dispersed benzoyl.
  • compositions for a more practical and fast topical application.
  • Foams help to overcome tolerance problems through better dose control, thanks to their spreading properties and low density.
  • compositions intended for a known topical application may cause side effects which may limit their use and therefore their effectiveness.
  • actives have the major disadvantage of inducing irritation that may result in poor tolerance of the product. This can thus create on the part of the patient a behavior of non-observance of the treatment and the discontent with regard to said treatment.
  • BPO benzoyl peroxide
  • BPO is particularly known to be difficult to tolerate by consumers following an acne treatment. This tolerance vis-à-vis the BPO is very variable depending on the formula used as a vehicle. The patient also often the impression that by applying more product, it will go towards a faster healing. This behavior leads to excessive irritation and discontinuation of treatment.
  • composition according to the invention has the advantage of being in the form of a foam generated extemporaneously and very well tolerated. After its application, the composition according to the invention is not removed by rinsing.
  • composition of the invention is to be particularly well tolerated, despite not being rinsed out, as shown by the examples illustrating one of the methods of assessing tolerance presented hereinafter.
  • Aerosols in which the foam is generated by a propellant gas but with the disadvantage of being aerosols with the risks well known to them (pollution, respiratory risks in particular).
  • Foaming formulas that are not very rich in foaming surfactants but packaged in a package provided with a mechanical foam generating system (pump with pulvorex type grid).
  • This type of formulation has the disadvantage of not being compatible with the use of dispersed active ingredients, and requires the use of foaming surfactants that can induce irritation in rinsed products.
  • the object of the present invention is therefore to provide a composition that meets these needs.
  • Foaming surfactants are defined as surfactants which produce a voluminous, stable and unctuous foam when they are mixed with water according to the tests well known to those skilled in the art.
  • Foaming surfactants include anionic surfactants, cationic surfactants, amphoteric surfactants and nonionic surfactants of the alkylpolyglucoside and glucamide family.
  • the dosage form according to the invention has the advantage of ensuring good stability of adapalene and BPO.
  • this formulation advantageously leads to the production of a soft, perfectly tolerated and non-irritating foam, which allows a better coverage of the area to be treated and makes it possible to overcome the problems of tolerance by a better control of the dose, thanks to the spreading properties and the low density of the foam.
  • this dosage form does not require for its implementation the use of propellants or aerosols.
  • aerosol or spray foams are excluded from the scope of the invention.
  • foams of the prior art of expanded cream type and / or foaming formulas requiring a mechanical foam generating system are also excluded from the invention.
  • the present invention finally relates to the cosmetic use of the composition according to the invention, by topical application of this composition to the skin, and a medicament for topical application to the skin, comprising such a composition.
  • the present invention will be described in more detail in the following description and examples, and in view of the Figurel attached to this application.
  • FIG. 1 shows photographs of a first composition according to the invention obtained by mixing the two intermediate compositions A5 and B7 described in the examples, immediately after mixing them and then when the reaction between these two compositions is complete (volume maximum foam).
  • composition according to the invention is capable of taking the form of a foam by the mere fact of its composition and can also be defined as a foaming composition for topical application.
  • the present invention accordingly, as a first object, a composition containing adapalene and benzoyl peroxide dispersed for topical application not rinsed being in the form of a foam, preferably of semi-solid consistency, containing no advantageously no foaming surfactant, and comprising a cosmetically or pharmaceutically compatible medium with topical application not rinsed especially on the skin and superficial body growths.
  • composition in the form of a foam (also hereinafter referred to as self-foaming composition), is meant a composition of semi-solid consistency having an aerated form comparable to a foam.
  • composition according to the invention is a self-foaming composition which comprises at least the following ingredients:
  • the self-foaming composition comprises at least two compositions or intermediate formulas in variable proportions and in particular the following ingredients:
  • composition or intermediate formula A At least one composition or intermediate formula A,
  • composition or intermediate formula B At least one composition or intermediate formula B,
  • adapalene contained in at least one of the intermediate compositions
  • benzoyl peroxide contained in at least one of the intermediate compositions.
  • the gas generating agent is present in one of the intermediate formulas mentioned above.
  • the self-foaming composition comprises at least two compositions or intermediate formulas in variable proportions and in particular the following ingredients:
  • composition or intermediate formula A comprising an activating agent for the gas-generating agent
  • composition or intermediate formula B comprising the gas generating agent
  • benzoyl peroxide and adapalene are present in the same intermediate formula A or B.
  • the composition is self-foaming, that is to say it foams by simple mixing of the intermediate compositions A and B.
  • each intermediate composition may have a viscosity (measured at 25 ° C. and at atmospheric pressure) of between 1 cP and 500,000 cP, advantageously between 500 cP and 350,000 cP, measured with a conventional method of type brookfield RV dv II: Needle 6 lives 2.
  • the gas generated by the gas-generating agent may be any physiologically compatible gas that makes it possible to obtain a foam, such as, for example, carbon dioxide (CO 2 ) or oxygen (O 2 ).
  • the gas concentration can vary, the amount of bubbles in the composition can vary and thus give a composition that can go from unventilated to very highly aerated.
  • the term "activating agent of the gas generating agent” means an ingredient which, by chemical reaction with the gas generating agent, releases a gas. Preferably it is an acid / base reaction.
  • the self-foaming composition may be preferably in all forms ranging from aerated to a very expanded foam.
  • composition according to the invention is suitable for topical application and may further comprise a physiologically acceptable medium, that is to say a medium compatible with the skin and superficial body growths. It is preferably a cosmetically or pharmaceutically acceptable medium.
  • the composition may comprise any active agent capable of exhibiting an activity, which may be therapeutic.
  • active agents may be, among others, chosen from emollient agents, humectants, anti-radical agents, anti-inflammatory agents, vitamins, depigmenting agents, anti-acne agents, anti-seborrhics agents, anti-fungal agents, keratolytic agents, sunscreens, slimming agents, skin coloring agents.
  • the self-foaming composition (that is to say, ready to be applied) may have a pH of between 2 and 8, preferably between 3 and 7.
  • the present invention relates either to a single compartmentalized container (each compartment hosting an intermediate formula) and preferably comprising 2 or 3 compartments or a kit comprising each intermediate formula stored independently of one another and physically separated.
  • the intermediate composition (or formula) A may be in the form of a solution, an emulsion (lotion, cream, cream without emulsifier, milk, fluid cream) or a gel.
  • This composition advantageously contains the activating agent for the gas generating agent, preferably an acid in sufficient quantity (which may be in the form of an acid / base buffer at acidic pH) which may be by way of non-limiting example the citric acid / sodium citrate couple.
  • Formula B can be in the form of a solution, a gel, an emulsion (lotion, cream, cream without emulsifier, milk, fluid cream).
  • This composition advantageously contains in sufficient quantity a gas generating agent, which may in particular be sodium bicarbonate.
  • the subject of the invention is also a kit or a single multi-compartment container as defined above, enabling the extemporaneous preparation of a self-foaming composition according to the invention, comprising separately at least two intermediate formulas (or intermediate compositions):
  • an intermediate formula A comprising at least one activating agent for the gas generating agent
  • an intermediate formula B comprising at least one gas generating agent
  • benzoyl peroxide being contained in at least one of said intermediate formulas A and B, and adapalene being contained in the other intermediate formula, or alternatively benzoyl peroxide and adapalene contained in the same formula intermediate A or B.
  • the benzoyl peroxide is contained in the intermediate composition A.
  • the adapalene is contained in the intermediate composition A.
  • the activating agent of the gas-generating agent (also referred to as "gas-activating agent”) is a compound which reacts with the gas generating agent by a chemical reaction (preferably an acid-base reaction) releasing a gas.
  • the acid / base buffer of said acid may be any acidic buffer / base of the weak acid such as, for example, a citric acid / sodium citrate buffer or a tartaric acid / sodium tartrate buffer.
  • the alpha-hydroxy acids which are weak acids preferably having a pKa of between 2 and 6 such as citric acid, tartaric acid, malic acid, lactic acid but also acid phosphoric acid and pyrophosphoric acid and their partially salified salts such as disodium pyrophosphate or sodium dihydrogenphosphate still called monosodium phosphate.
  • the gas-activating agent is chosen from a tartaric acid / tartrate salt buffer (for example sodium tartrate); citric acid / sodium citrate buffer alone; phosphoric acid, monosodium phosphate, disodium pyrophosphate alone or as a mixture with citric acid / sodium citrate buffer.
  • a tartaric acid / tartrate salt buffer for example sodium tartrate
  • citric acid / sodium citrate buffer alone phosphoric acid, monosodium phosphate, disodium pyrophosphate alone or as a mixture with citric acid / sodium citrate buffer.
  • the gas-activating agent is a citric acid / sodium citrate buffer alone or in admixture with monosodium phosphate and / or disodium pyrophosphate.
  • the content of citric acid / sodium citrate is preferably less than or equal to 2.4% relative to the total weight of the intermediate composition A, so as to limit any risk. tingling.
  • the citric acid / sodium citrate buffer is used in admixture with disodium pyrophosphate or sodium dihydrogenphosphate.
  • said gas-activating agent may be present in the intermediate formula A in an amount ranging from 0.001% to 95% by weight relative to the total weight of the intermediate formula A.
  • gas generating agent any agent that has the property of generating a gas by chemical reaction.
  • the gas that can be used in formula B may be carbon dioxide (C0 2 ).
  • the gas generated from the gas generating agent present in the intermediate composition B is preferably carbon dioxide or carbon dioxide (CO 2 ).
  • the gas generating agent is preferably selected from sodium bicarbonate, potassium bicarbonate, sodium carbonate, potassium carbonate and mixtures thereof.
  • the intermediate formula B comprises a carbon dioxide generating agent which is particularly preferably sodium bicarbonate.
  • Said gas generating agent may be present in intermediate formula B in an amount ranging from 1% to 10%, preferably from 2% to 8% by weight relative to the weight of formula B.
  • the intermediate formula A may have an acidic pH, advantageously between 1.0 and 6.0, and the intermediate formula B may have a basic pH, advantageously between 7 and 12.
  • one or more intermediate formula (s) A and B described above comprises benzoyl peroxide in an amount ranging from 0.0001% to 20% benzoyl peroxide, preferably 0.025% by weight. % to 10%, even more preferably 2.5% to 5% by weight relative to the weight of the total composition.
  • total composition or “total formula” means the composition of the product in the form of foam after the mixing of said intermediate compositions.
  • the BPO is contained in the intermediate composition A which has a preferably acidic pH in order to optimize its stability.
  • one or more intermediate formula (s) A and B described above comprises adapalene (that is, 6- (3- (1 - adamantyl) -4-methoxyphenyl) -2-naphthoic acid or its methyl ester, or a salt thereof) in an amount ranging from 0.0001% to 20% by weight relative to the weight of the total composition.
  • adapalene that is, 6- (3- (1 - adamantyl) -4-methoxyphenyl) -2-naphthoic acid or its methyl ester, or a salt thereof
  • the composition according to the invention comprises from 0.001% to 5% and more preferably from 0.01% to 1% by weight of adapalene relative to the total weight of the total composition. More preferentially, the composition comprises from 0.01% to 0.5%, better still from 0.1% to 0.4% by weight of adapalene, and still more preferably from 0.1% to 0.3% by weight of adapalene. relative to the weight of the total composition.
  • adapalene salts means salts formed with a pharmaceutically acceptable base, in particular mineral bases such as sodium hydroxide, potassium hydroxide and aqueous ammonia, or organic bases such as lysine, arginine or N-methyl. -glucamine; and salts formed with fatty amines such as dioctylamine and stearylamine.
  • Intermediate formula A may be in any galenic form compatible with the desired dosage form for the final composition obtained by mixing formula A with formula B.
  • Advantageously formula A may be a gel, a solution or a suspension an emulsion (cream, cream without surfactant, lotion, milk, fluid cream), preferably a gel guaranteeing the suspension of BPO.
  • the intermediate formula A is a gel.
  • Intermediate formula B can be in any galenic form compatible with the desired dosage form for the final composition obtained by mixing formula B with formula A.
  • Advantageously formula B can be a gel, a solution, a suspension, a emulsion (cream, cream without surfactant, milk lotion, fluid cream), preferably an emulsion.
  • the intermediate formula B is an emulsion, and contains a fatty phase containing one or more oils as described below.
  • Each intermediate formula of the multi-compartment kit or container as defined above, according to the invention comprises a physiologically acceptable medium, carrying the compound (s), and chosen in such a way that the compounds are capable of reacting with each other. other for forming a self-foaming composition upon mixing of at least intermediate formulas A and B.
  • the gas-generating agent such as sodium bicarbonate
  • the gas-activating agent such as the acid
  • the kit or the single multi-compartment container according to the invention can be designed so that during the preparation of the composition according to the invention, the intermediate formulas A and B can be mixed in a ratio by weight AB ranging from 0.5 to 2, preferably from 0.5 to 1.5, more preferably close to 1 (that is to say from 0.9 to 1, 1), and even more preferably from 1.
  • the kit can be designed to simultaneously release doses (by weight) of intermediate compositions A and B which can be in a ratio by weight ranging from 2 doses of B for 1 dose of A to 2 doses of A for 1 dose of B, preferably 2 doses of B for 1 dose of A at 3 doses of A for 2 doses of B.
  • the kit is designed to simultaneously release 1 dose by weight of A and 1 dose by weight of B.
  • the kit may be in any form compatible with, on the one hand, a separate preservation of the intermediate formulas A and B and, on the other hand, the ability to extemporaneously carry out the mixture of A and B.
  • intermediate formulas A and B may be in a housing with at least two separate compartments, each containing A or B.
  • the kit may be in the form of a syringe with at least two separate bodies, each provided with a piston, said two bodies containing A and B, and being designed to release simultaneously by exercise of a force on the piston the desired doses of A and B.
  • the invention also relates to a method for preparing a composition according to the invention, characterized in that to obtain the self-foaming composition, an intermediate formula A and an intermediate formula B of the kit are mixed extemporaneously as defined above.
  • high, in relative proportions by weight AB may range from 0.5 to 2, preferably from 0.5 to 1, 5 and more preferably from 1.
  • gas-generating agent preferably sodium bicarbonate
  • gas-activating agent preferably citric acid and / or disodium pyrophosphate and / or sodium dihydrogen phosphate or monosodium phosphate.
  • the ratio of citric acid / sodium bicarbonate is advantageously between 0.1 and 2, preferably between 0.5 and 1, and very preferably equal to 0.7.
  • the disodium pyrophosphate / sodium bicarbonate ratio is between 0.5 and 5, preferably between 1 and 3, and very preferably is equal to at 2.4.
  • the sodium dihydrogenphosphate monohydrate / sodiumbicarbonate ratio is between 0.5 and 5, preferably between 1 and 3, and very preferably is equal to 2.
  • Example 4 The exemplification of ratios sodium bicarbonate / citric acid, sodium bicarbonate / sodium pyrophosphate, sodium bicarbonate / sodium hydrogen phosphate is described in Example 4.
  • the combination citric acid / sodium citrate, disodium pyrophosphate and a gelling system compatible with the dosage form has made it possible to obtain a formula with very stable physicochemical properties (see Table I) and in which the BPO is particularly stable (see Table II), generating no unpleasant sensation on the skin and allowing the release of gas and thus the creation of foam.
  • a composition is considered physically stable when its organoleptic characteristics, pH, viscosity and homogeneity of BPO do not change with time under different temperature conditions: ambient temperature (RT), 30 ° C and 40 ° C.
  • the ambient temperature corresponds to a temperature ranging from 15 ° C to 25 ° C.
  • composition is considered chemically stable when the content of active ingredient it contains does not change with time under the different temperature conditions (RT, 30 ° C and 40 ° C)
  • the composition is considered stable when the BPO content (expressed by weight relative to the weight of the intermediate formula) is included in the specifications ranging from 90% to 1 10%.
  • composition according to the invention may also comprise one or more agents chosen from dispersing agents, solubilizing agents, stabilizing agents, preserving agents, fatty substances, thickening agents, dyes, perfumes, surfactants, gelling agents, complexing agents, neutralizing agents, non-foaming emulsifiers, fillers, sequestering agents, reducing agents, odor masks, plasticizing agents, softening agents, moisturizing agents, pigments, clays, mineral fillers, mineral colloids, polymers, proteins, pearlescent agents, waxes, oils such as paraffins, silicones, fatty acids, solid esters of fatty alcohol or fatty acids , gums, wetting agents.
  • Water-soluble dyes such as FD & C Blue 1 (of formula and liposoluble dyes such as Sudan Red III or Red Nil have the advantage of coloring one of the formulation intermediates. This coloration makes it possible to control the good mixture of the two formulation intermediates and to enhance the formation of the foam. This coloration is in particular presented in the examples and in FIG. GELIFYING AGENTS OF THE INTERMEDIATE FORMULA CONTAINING THE GAS ACTIVATOR
  • the intermediate composition A advantageously containing at least one gas-activating agent preferably contains at least one gelling agent and / or suspending agent.
  • Gels containing BPO are known to be very complicated to stabilize. The viscosity and the suspensive power of these formulas are often hard to guarantee over time. In addition, the formation A can contain large amounts of acid and electrolytes.
  • gelling agents and / or suspending agents resistant to both BPO, electrolytes and acidic pHs that can be used in compositions A according to the invention
  • ready-to-use mixtures such as Polyacrylate-13 & Polyisobutene & Polysorbate 20 sold by Seppic under the name Sepiplus 400®
  • polysaccharides with, by way of nonlimiting examples, xanthan gum such as Xantural180® sold by Kelco, gellan gum sold under the KelcoGel® name by Kelco, the Sclerotium Gum sold under the name Amigel® by Alban Muller Industry, guar gum and its derivatives such as Hydroxypropyl Guar sold under the name Jaguar HP-105® resold by Rodhia
  • cellulose and its derivatives such as microcrystalline cellulose and sodium carboxymethyl cellulose sold under the name Blanose CMC 7H4XF® by the company Hercules, hydroxypropylmethylcellulose, in particular the product sold under the name Methoc
  • Vegum K® and Xantural 180® will be used in combination.
  • the gelling agent as described above may be used at preferential concentrations ranging from 0.001% to 15% and, more preferably, ranging from 0.15% to 5% by weight relative to the weight of the intermediate formula A.
  • acrylic acid polymers such as Acrylates / C 10-30 Alkyl Acrylate Crosspolymer such as carbomers known as non-electrolyte sensitive, sold under the name Ultrez 20®, Ultrez 10®, Carbopol 1382® or Carbopol ETD2020NF®, AQUA SF1 ® sold by the company Lubrizol, the Ammonium Acrylate / Acrylamide Copolymer & Polyisobutene & Polysorbate 20 mixture sold by Seppic under the name Sepiplus 265®, the polysaccharides with, by way of nonlimiting examples, xanthan gum such as Xantural180® sold by Kelco, gellan gum sold under the name Kelcogel® by Kelco, Sclerotium Gum sold under the name Amigel® by Alban Muller
  • the gelling agent as described above may be used at preferential concentrations ranging from 0.001% to 15% and, more preferably, ranging from 0.15% to 5% by weight relative to the weight of the intermediate formula B.
  • composition according to the invention may contain one or more wetting agents.
  • this or these wetting agents are present in each intermediate composition which contains BPO and / or adapalene.
  • wetting agents whose role is to reduce the surface tension and to allow the BPO and the adapalene to be incorporated more easily in the formula and mainly at the time of its grinding, preferentially, this list is not limiting.
  • a wetting agent which may preferentially present an HLB of 10 to 14, compounds of the Poloxamers and / or glycols family and more particularly Synperonic PE / L44® and / or Synperonic PE / L62® and / or compounds such as that propylene glycol, dipropylene glycol, propylene glycol dipelargonate, lauroglycol, ethoxydiglycol, preferably the wetting agents are in liquid form so as to easily incorporate into the composition without the need to heat it .
  • the particularly preferred wetting agent is LUTROL L44® sold by BASF. ®
  • HUMECTANT AGENTS Among the humectants and / or emollients whose role is to moisturize the skin and to facilitate the application of the formulation, optional use is made, without this list being limiting, of compounds such as a polyol which is miscible with water.
  • water at ambient temperature especially chosen from polyols having in particular from 2 to 20 carbon atoms, preferably having from 2 to 10 carbon atoms, and preferably having from 2 to 6 carbon atoms, such as glycerol, glycol derivatives such as propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, dipropylene glycol, diethylene glycol and mixtures thereof, but also sugars (for example glucose, lactose), polyethylene glycol (PEG) (for example Lutrol E400®), urea, amino acids (for example serine, citrulline, arginine, asparagine, alanine).
  • polyols having in particular from 2 to 20 carbon atoms, preferably having from 2 to 10 carbon atoms, and preferably having from 2 to 6 carbon atoms, such as glycerol, glycol derivatives such as propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, diprop
  • humectant and / or emollient preferred agent mention may be made of glycerin and propylene glycol.
  • the humectants may be used, alone or in combination, at preferential concentrations ranging from 0.001% to 30% and, more preferably, ranging from 0.01% to 10% by weight relative to the weight of the total formula.
  • chelating agents that may be mentioned as non-limiting examples are ethylene diamine tetraacetic acid (EDTA), diethylene triamine penta-acetic acid (DTPA) and ethylene diamine di (O-hydroxyphenyl) acid.
  • acetic acid) EEDDA
  • 2-hydroxyethylenediamine triacetic acid HEDTA
  • EDDHMA ethyldiamine-di (O-hydroxy-p-methylphenyl) acetic acid
  • EEDCHA ethylene diamine di (5 -carboxy-2-hydroxyphenyl) acetic acid
  • EDTA ethylene diamine tetraacetic acid
  • composition according to the invention may contain one or more cosmetic active ingredients such as, for example, allantoin with anti-irritant properties, zinc gluconate (anti-acne), dipotassium glycyrrhizate for these anti-inflammatory properties or still alpha bisabolol healing.
  • cosmetic active ingredients such as, for example, allantoin with anti-irritant properties, zinc gluconate (anti-acne), dipotassium glycyrrhizate for these anti-inflammatory properties or still alpha bisabolol healing.
  • Fillers and / or particles can be used to stabilize and boost the foam. Some of them have the particular property of being placed at the interface water / air and thus stabilize this interface. As fillers, mention may be made of talc, metal oxides such as zinc oxide and TiO 2 T2000 titanium dioxide sold by the company.
  • composition according to the invention may also comprise a fatty phase.
  • This fatty phase may comprise, for example, vegetable, mineral, animal or synthetic waxes, oils or butters, silicone oils and their mixtures of emulsifiers. Because of the instability of the BPO with respect to the lipophilic molecules, the fatty phase will preferably be contained in the basic phase containing the gas activator.
  • composition according to the invention may also comprise a fatty phase.
  • This fatty phase may comprise, for example, waxes, oils or vegetable, mineral, animal or synthetic butters, silicone oils, and mixtures thereof.
  • the fatty phase may be present in one and / or the other of the intermediate compositions A and B.
  • the fatty phase may comprise from 0% to 95% by weight relative to the weight of each intermediate formula.
  • the fatty phase of the composition according to the invention may comprise, for example, vegetable, mineral, animal or synthetic oils, silicone oils, and mixtures thereof.
  • mineral oil there may be mentioned, for example, paraffin oils of different viscosities such as Primol 352®, Marcol 82®, Marcol 152® sold by the company Esso.
  • sweet almond oil there may be mentioned sweet almond oil, palm oil, soybean oil, sesame oil, sunflower oil, olive oil.
  • animal oil or their substitute of vegetable origin mention may be made of lanolin, squalene, fish oil, with as derivative perhydrosqualene sold under the name Sophiderm® by Sophim.
  • esters such as cetearyl isononanoate such as the product sold under the name Cetiol SN PH® by Cognis France, isononyl isononanoate such as DUB ININ® sold by Stéarine Dubois, diisopropyl adipate such as the product sold under the name Crodamol DA® by Croda, isopropyl palmitate, such as the product sold under the name Crodamol IPP® by Croda, caprylic capric triglyceride such as Miglyol 812® sold by the company Univar.
  • Parleam® sold by Rossow.
  • silicone oil there may be mentioned a dimethicone such as the product sold under the name Q7-9120 Silicone Fluid® with a viscosity of 20 to 12500 is by the company Dow Corning, a cyclomethicone such as the product sold under the name ST- Cyclomethicone 5NF® also by Dow Corning or De 9045 Elastomer Blend® also by Dow Corning.
  • a dimethicone such as the product sold under the name Q7-9120 Silicone Fluid® with a viscosity of 20 to 12500 is by the company Dow Corning
  • a cyclomethicone such as the product sold under the name ST- Cyclomethicone 5NF® also by Dow Corning or De 9045 Elastomer Blend® also by Dow Corning.
  • composition according to the invention can also comprise solid fatty substances such as natural or synthetic waxes, fatty acids such as stearic acid, fatty alcohols such as Speziol C18® pharma or Speziol C16® sold by the company Cognis, and texture agents of the tribehenate type, such as Compritol 888® sold by the company Gattefossé or hydrogenated castor oils such as Cutina HR® sold by the company Cognis or the glyceryl stearate such as GELEOL® sold by the company Gattefossé.
  • These non-liquid fatty substances may be used alone or as a mixture of 0 to 30% by weight relative to the weight of the total formula.
  • an exceptional foam quality has been observed when fatty alcohols of formula CH 3 (CH 2) n OH (n is between 11 and 23) are present at contents greater than 1% by weight relative to the weight of the total formula .
  • composition according to the invention may also comprise nonionic emulsifiers. These are in particular present in the intermediate formula or formulas which contain a fatty phase (emulsions).
  • the self emulsifying Wax sold by Croda under the name of Polawax NF®.
  • the surfactants that can be used are the polyglycerol esters, which are esters of polyglycerin
  • Emulium Kappa® and Emulium Delta® sold by Gattefosse These active Tensio can be used alone or in combination so that the HLB of the system is greater than 12 and preferably greater than 15.
  • Such emulsifiers can be used in contents ranging from 0.01% to 30% by weight relative to the weight of the total composition, preferably from 0.1% to 15%, and more preferably from 0.5% to 7%.
  • preservatives examples include benzalkonium chloride, bronopol, chlorhexidine, chlorocresol and its derivatives, ethyl alcohol, phenoxyethanol, potassium sorbate, diazolidinyl urea, benzyl alcohol, parabens, sodium benzoate or mixtures thereof.
  • Step 1 At a temperature above 60 ° C, add with stirring the gelling agents and then the activating agent (s) of the gas generator to the main water phase.
  • Step 2 At the same time perform the grinding phase containing BPO, water, Propylene glycol and Poloxamer 124 under high shear.
  • Step 3 At a temperature below 30 ° C add the mixture from Step 2 to the main phase of Step 1.
  • Step 4 Add additives such as pure Blue 1 dye or in solution.
  • adapalene is not present in the intermediate composition B, it can be introduced into each of the formulas A below in step 2.
  • the quantities are expressed as a percentage with respect to the weight of the intermediate formula and not with respect to the weight of the total formula (the term "total formula" means the mixture of the two intermediate formulas).
  • Step 1 ' At a temperature above 60 ° C add stirring the gelling agents to the main water phase.
  • Step 2 At the same time, heat the fatty phase (containing the oils, the waxes and the surfactants) to a temperature above 60 ° C.
  • Step 3 ' At a temperature above 60 ° C make the emulsion by adding the fat phase to the main phase from step 1'.
  • Step 4 Add additives such as preservatives or ethanol at a temperature suitable for the additive.
  • Step 5 ' Neutralize the mixture.
  • Step 6 ' At a temperature below 40 ° C add the sodium bicarbonate.
  • adapalene is not present in intermediate composition A, it can be introduced into each of formulas B below in step 2 '.
  • the amounts are expressed as a percentage with respect to the weight of the intermediate formula and not with respect to the weight of the total formula.
  • the table below represents the mixtures in a 1: 1 weight ratio of the intermediate compositions A and B described above.
  • a cross at the intersection of two formulation intermediates indicates that mixing is possible and generates a foam with the desired properties.
  • the adapalene is introduced into one or other of these two compositions A and B, in a content ranging from 0.1 to 0.3% by weight relative to the weight. of the total formula, that is to say 0.2 to 0.6% by weight relative to the weight of the composition A or composition B.
  • adapalene is added to the composition A.
  • the formulas employed are: Formula A5 to which a blue dye (FD & C Blue 1, in a content of 0.0009% by weight with respect to the total weight of the formula A5) has been added; and the formula B7.
  • the objective of this study is to evaluate the tolerance of the supports of complete and intermediate formulas on reconstructed human epidermis (RHE, Episkin model) through:
  • the tested formulas are:
  • An intermediate composition of acid formulation A7 example placebo (that is to say, not containing BPO),
  • Measurements of MTT according to the current OECD protocol indicate that all formulas tested are non-irritating.
  • EXAMPLE 4 The ideal content of citric acid, sodium pyrophosphate and sodium dihydrogenphosphate monohydrate was established empirically to react with 5% sodium bicarbonate. The values are expressed in percent weight / weight with respect to the weight of each of the two intermediate formulas.
  • buffer citric acid / sodium citrate may advantageously be substituted with disodium pyrophosphate and vice versa as the contents cited by way of example in Table III below:
  • Table III the values are expressed in weight / weight percentage with respect to the weight of each of the two intermediate formulas E 1 E 2 E 3 E 4 E 5 E 6 E 7
  • Citric acid 3.5% 1 .75% 1 .4% 0 2.1% 1 .05% 0
  • citric acid / sodium citrate buffer may advantageously be substituted with sodium dihydrogen phosphate monohydrate and vice versa, as the contents cited by way of example in Table IV below:
  • Table IV The values are expressed as a weight / weight percentage relative to the weight of each of the two intermediate formulas
  • the amount of citric acid is greater than or equal to 1, 4, the amount of foam is optimal when the disodium pyrophosphate is present in the composition according to the following equation:
  • [B] weight content of sodium bicarbonate in the intermediate composition B

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP15712387.8A 2014-03-28 2015-03-27 Chemischer adapalen und benzoylperoxid enthaltender ungespülter schaum Not-in-force EP3122322B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461971649P 2014-03-28 2014-03-28
PCT/EP2015/056784 WO2015144906A1 (fr) 2014-03-28 2015-03-27 Mousse chimique non rincée contenant de l'adapalene et du peroxyde de benzoyle

Publications (2)

Publication Number Publication Date
EP3122322A1 true EP3122322A1 (de) 2017-02-01
EP3122322B1 EP3122322B1 (de) 2018-09-26

Family

ID=52814080

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15712387.8A Not-in-force EP3122322B1 (de) 2014-03-28 2015-03-27 Chemischer adapalen und benzoylperoxid enthaltender ungespülter schaum

Country Status (11)

Country Link
US (1) US20180185283A1 (de)
EP (1) EP3122322B1 (de)
JP (1) JP6740134B2 (de)
KR (1) KR20160137593A (de)
CN (1) CN106456544B (de)
AU (1) AU2015238223B2 (de)
BR (1) BR112016022299A2 (de)
ES (1) ES2702646T3 (de)
MX (1) MX2016012366A (de)
RU (1) RU2016142284A (de)
WO (1) WO2015144906A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110785161B (zh) 2017-06-23 2023-06-20 宝洁公司 用于改善皮肤外观的组合物和方法
CA3102288A1 (en) 2018-07-03 2020-01-09 The Procter & Gamble Company Method of treating a skin condition
WO2021247496A1 (en) 2020-06-01 2021-12-09 The Procter & Gamble Company Method of improving penetration of a vitamin b3 compound into skin
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100631000B1 (ko) * 1997-11-07 2006-10-04 가부시끼가이샤 메디온 리서치 라보라토리즈 이산화탄소 함유 점성 제약 조성물
US6177092B1 (en) * 1998-11-10 2001-01-23 Color Access, Inc. Self-foaming cleansing systems
NZ541526A (en) * 2003-01-24 2008-03-28 Stiefel Res Australia Pty Ltd Clindamycin phosphate foam
US20050123487A1 (en) * 2003-12-08 2005-06-09 Spadini Alessandro L. Stable nonaqueous liquid reactive skin care and cleansing packaged product
BRPI0709674A2 (pt) * 2006-03-31 2011-12-06 Stiefel Res Australia Pty Ltd gel de suspensão espumante
WO2009069006A2 (en) * 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
DE102008029357A1 (de) * 2008-06-20 2009-12-24 Schwan-Stabilo Cosmetics Gmbh & Co. Kg Schäumende kosmetische Zubereitung
FR2969492B1 (fr) * 2010-12-23 2013-07-05 Galderma Res & Dev Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant de l'adapalene
FR2969493B1 (fr) * 2010-12-23 2013-07-05 Galderma Res & Dev Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant du bpo
FR2969491B1 (fr) * 2010-12-23 2013-07-12 Galderma Res & Dev Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant une combinaison d'adapalene et de bpo
MX361338B (es) * 2014-03-28 2018-12-04 Galderma Res & Dev Espuma quimica que se remueve con enjuague que contiene peroxido de benzoilo.
CN106456543B (zh) * 2014-03-28 2021-01-22 盖尔德马研究及发展公司 包含过氧化苯甲酰的免洗型化学泡沫

Also Published As

Publication number Publication date
AU2015238223A1 (en) 2016-10-06
CN106456544B (zh) 2021-02-02
US20180185283A1 (en) 2018-07-05
WO2015144906A1 (fr) 2015-10-01
ES2702646T3 (es) 2019-03-04
RU2016142284A (ru) 2018-05-04
AU2015238223B2 (en) 2020-07-30
BR112016022299A2 (pt) 2017-08-15
EP3122322B1 (de) 2018-09-26
CN106456544A (zh) 2017-02-22
JP2017508767A (ja) 2017-03-30
MX2016012366A (es) 2016-12-02
JP6740134B2 (ja) 2020-08-12
KR20160137593A (ko) 2016-11-30

Similar Documents

Publication Publication Date Title
EP3122325B1 (de) Chemischer benzoylperoxid enthaltender ungespülter schaum
EP3122324B1 (de) Chemischer benzoylperoxid enthaltender gespülter schaum
EP3355869B1 (de) Selbstschäumende reinigungszusammensetzung mit ivermectin zum ausspülen
EP3355857A1 (de) Chemischer schaum ohne ausspülen mit trifaroten und verwendung davon bei der behandlung von akne
EP3122322B1 (de) Chemischer adapalen und benzoylperoxid enthaltender ungespülter schaum
EP3355868B1 (de) Chemischer schaum ohne ausspülen mit clobetasolpropionat und verwendung davon bei der behandlung von psoriasis
WO2017055297A1 (fr) Mousse chimique non rincée contenant du trifarotène, et son utilisation dans le traitement de l'ichtyose
EP3355858B1 (de) Spülfreier chemischer schaum mit brimonidin und verwendung davon bei der behandlung von rosacea
EP3355866B1 (de) Selbstschäumende reinigungszusammensetzung mit clobetasolpropionat und verwendung davon bei der behandlung von psoriasis
FR3041541A1 (fr) Mousse chimique non rincee comprenant de l'ivermectine

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20160928

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BUGE, JEAN-CHRISTOPHE

Inventor name: NADAU-FOURCADE, KARINE

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180216

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602015016954

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0008368000

Ipc: A61K0009460000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/46 20060101AFI20180508BHEP

Ipc: A61Q 19/00 20060101ALI20180508BHEP

Ipc: A61K 8/368 20060101ALI20180508BHEP

Ipc: A61K 8/04 20060101ALI20180508BHEP

Ipc: A61K 9/12 20060101ALI20180508BHEP

Ipc: A61K 47/10 20170101ALI20180508BHEP

Ipc: A61K 8/38 20060101ALI20180508BHEP

Ipc: A61K 31/327 20060101ALI20180508BHEP

Ipc: A61K 31/192 20060101ALI20180508BHEP

Ipc: A61Q 19/08 20060101ALI20180508BHEP

INTG Intention to grant announced

Effective date: 20180529

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1045173

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181015

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: FRENCH

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015016954

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181227

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2702646

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20190304

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1045173

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190126

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015016954

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20190627

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190327

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190327

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190331

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602015016954

Country of ref document: DE

Representative=s name: BOEHMERT & BOEHMERT ANWALTSPARTNERSCHAFT MBB -, DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20210211

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20150327

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20210402

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20220321

Year of fee payment: 8

Ref country code: DE

Payment date: 20220322

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20220322

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20230509

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220327

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220328

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602015016954

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20230327

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230327

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230327

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230331

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231003